FDA
-
-
-
-
-
-
-
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
-
-
-
-
-
-
-
Scienture secures $11 million in non-dilutive debt financing
-
-
-
-
-
-
-
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
-
-
-
-
-
-
-
SCIENTURE expands access for ARBLI oral losartan suspension
-
-
-
-
-
-
-
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
-
-
-
-
-
-
-
SCIENTURE secures rebate deal for liquid losartan drug formulary access
-
-
-
-
-
-
-
SCIENTURE Announces Executive Leadership Transition
-
330,009 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

